Discover and read the best of Twitter Threads about #ASCO2023
Most recents (3)
Hey #ASCO2023, keep following !
Let's have a 👀 at the LUNAR phase 3 trial,
showing an OS benefit with tumor treating fields (TTFs) in addition to SoC in platinum refractory meta NSCLC❗️
3.3 months median OS improvement,
Wow... a new SoC ❓
A few thoughts🧵👇
1/7
Let's have a 👀 at the LUNAR phase 3 trial,
showing an OS benefit with tumor treating fields (TTFs) in addition to SoC in platinum refractory meta NSCLC❗️
3.3 months median OS improvement,
Wow... a new SoC ❓
A few thoughts🧵👇
1/7
First the design :
OPEN LABEL 👇
+again and again, a restricted physician's choice
(see our work here : bit.ly/3DsYqPx)
but let's be fair, it's the same in both arms
2/7
OPEN LABEL 👇
+again and again, a restricted physician's choice
(see our work here : bit.ly/3DsYqPx)
but let's be fair, it's the same in both arms
2/7
Look at the OS ITT curve... 👇
OS benefit in platinum resistant lung cancer...
HR = 0.74 (0.56 - 0.98), p = 0.035
Ok ok...
BUT now let's talk about the OPEN LABEL design
3/7
OS benefit in platinum resistant lung cancer...
HR = 0.74 (0.56 - 0.98), p = 0.035
Ok ok...
BUT now let's talk about the OPEN LABEL design
3/7
Some toughts about the INDIGO phase 3 trial, vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma #ASCO2023
- setting = residual or recurrent disease
- primary EP = PFS = improved from 11.1 to 27.7 Mo (16.6)
Here are some toughts 🧵
1/6
- setting = residual or recurrent disease
- primary EP = PFS = improved from 11.1 to 27.7 Mo (16.6)
Here are some toughts 🧵
1/6
First, we can see that median time from diagnosis ≥ 2.5 years in both groups, so it really looks like mostly recurrent disease.
Now let's make some comparison with another trial, the "PCV trial" -->
This trial was in first-line patients ❗️
2/6
Now let's make some comparison with another trial, the "PCV trial" -->
This trial was in first-line patients ❗️
2/6
In INDIGO, the primary EP is PFS ...
and OS is a secondary EP which is ... far below in the clinicaltrial.gov list 👇
3/6
and OS is a secondary EP which is ... far below in the clinicaltrial.gov list 👇
3/6
1/6 #TumorBoardTuesday
🔬🧬@PGrivasMDPhD @rafee_talukder discussed variant histology #urothelialcarcinoma & cis-ineligible dz
➡️Thursday Case wrap up 🎀
🆓 #CME: answer 2 quick ❓
ALL CME 🔗: integrityce.com/TBT2023
CME eval🔗: integrityce.com/TBTeval23
🔬🧬@PGrivasMDPhD @rafee_talukder discussed variant histology #urothelialcarcinoma & cis-ineligible dz
➡️Thursday Case wrap up 🎀
🆓 #CME: answer 2 quick ❓
ALL CME 🔗: integrityce.com/TBT2023
CME eval🔗: integrityce.com/TBTeval23
2/6 #TumorBoardTuesday
Thurs Case🎀
Take🏠:
✅Variant hist UC changes tx
⬇️resp to plat 👉surg first, clin trial
✅Cis inelig mUC- acc approval: Enfortumab Vedotin + pembro 1L
✅Trials: 1L SG + IO, others
📚Here’s @PGrivasMDPhD @rafee_talukder’s thread
threadreaderapp.com/thread/1656086…
Thurs Case🎀
Take🏠:
✅Variant hist UC changes tx
⬇️resp to plat 👉surg first, clin trial
✅Cis inelig mUC- acc approval: Enfortumab Vedotin + pembro 1L
✅Trials: 1L SG + IO, others
📚Here’s @PGrivasMDPhD @rafee_talukder’s thread
threadreaderapp.com/thread/1656086…
@PGrivasMDPhD @rafee_talukder 3/6 #TumorBoardTuesday
Thursday Case🎀
🎞️ TBT in a video
Here’s the highlight reel:
Dr. Talukder & Grivas talk about:
🔹new approaches for cis ineligible disease
🔹variant histology
🙌 what to look forward to at #ASCO2023.
Check out the next tweet for the Director’s 🎬 cut!
Thursday Case🎀
🎞️ TBT in a video
Here’s the highlight reel:
Dr. Talukder & Grivas talk about:
🔹new approaches for cis ineligible disease
🔹variant histology
🙌 what to look forward to at #ASCO2023.
Check out the next tweet for the Director’s 🎬 cut!
